Skip to main content

The Apocalypse Is Open Us, Bacteria Develop Shareable Pan-resistance

Forget climate change, forget wars over religions and territory, a bigger and far scarier problem has reached a level where it will change the future beyond recognition.
Anti-biotic resistance has been a problem that has been getting bigger and bigger for years and whilst those who work in the health care community are aware and have been trying to minimise its effects for decades, the activities of the wider communities have taken us to the brink of a precipice from which we can't reverse.
Misuse of antibiotics - low level doses given by the farming industry to animals to promote growth, uncontrolled distribution to patients by GPs, and failure to complete prescribed courses by patients themselves - have driven the development of Superbugs. Bacteria that are able to resist the effects of some antibiotics.
Since the discovery of penicillin there has been an escalating war between pharmaceuticals and bacteria. When a new antibiotic is discovered a small number of bacteria aren't killed by the new drug and develop resistance to its effects. It passes this resistance down through generations and eventually this becomes widespread.
In the early days this resistance took decades to develop. However with the rise in the misuse of the antibiotics and the greater mobility of humanity that lag has been reducing. Previously there was sufficient time for new antibiotics to be developed to replace the outdated ones. That hasn't been the case for a while.
In fact it a new antibiotic becomes ineffective so rapidly that Pharmaceutical companies can no longer recoup their research investment. As a result no new antibiotics have been discovered since 1987.
The news that the antibiotic of last resort - colistin - is now no longer effective should be fundamentally terrifying. That this is the case thanks to its continued use in farming is infuriating. And the news that this new resistance can be passed between bacteria types means that we now have bacteria that are pan-resistant: they cannot be treated by any medicine we know today.
How does this affect you? The loss of antibiotics means that more and more operations will be fatal due to post-surgery infections. Cancer therapies, heavily reliant on antibiotics would become more deadly than the growths they seek to control. Complications in childbirth will be fatal for mother and infant. And even seemingly minor cuts and scrapes will lead to amputations and deaths.
Healthcare effectiveness will have regressed to the 19th Century.
Organisations are predicting that 11 million people a year could die from infections alone. That's higher than the number of people who died annually in World War 1 or 2.
What can be done about it? Governments need to move quickly. Firstly to prevent the misuse of antibiotics, particularly in the farming industry. Secondly by funding research into new antibiotics which might replace colistin and thirdly by supporting the development of technologies that might provide a drug-free way to kill these infections.
Unfortunately the time to do this has passed. Action taken now might minimise the global effects of a pandemic to which we currently have no answer.


Popular posts from this blog

F1: Robert Kubica Impresses In Renault Test Run

The car may be old but its the performance of the driver that's the story here. Robert Kubica returned to F1, after a fashion, earlier this week with an extensive test run in a 2012 Lotus Renault F1 car at Valencia.
The age of the car and the circuit were likely determined by F1's current rules which ban testing, but the reason for Kubica being in the car is far more interesting. Considered by many to be a potential World Champion and certainly one of the fastest drivers of his generation, Kubica's F1 career seemed to be over after a 2011 crash whilst driving in the Rally of Andora. His Skoda Fabia was penetrated by a guardrail in the high speed accident partially severing his right arm.
Up until last year Kubica has been competing in rallying, with the expectation that the limited movement in his repaired arm would prohibit a return to single seater racing.
So this week's test is both interesting and confusing. Interesting because Kubica completed 115 laps of the ret…

Panos Panay's Defence Of Microsoft Surface Hardware Sounds Eerily Familiar

This weekend I went out with my ten year old daughter to select a laptop for her school year beginning in January. The schools requirements are quite specific, requiring a Windows 10 device, with a preference for a touchscreen and a stylus. She chose a Surface Pro, after trying a large number of different options. Having seen the way I use my own Surface Pro - and tried it herself there was only ever going to be two options - and the other was a Surface Laptop.
I tell you this so that you understand I am a buyer of Microsoft's products through choice, not compulsion. I'm on my third Surface device now. 
So when Panos Panay dismissed reports of the death of the Surface hardware line, I was very interested to see exactly how strong these denials were. Especially how they reflect what has gone before. To whit: Windows 10 Mobile.
Panay claimed that Microsoft is in hardware for the long haul. Almost exactly mirroring the words of Terry Myerson, when he claimed Windows Mobile was g…

WhartonBrooks Indiegogo Windows 10 Mobile Even More Doomed To Failure Than Usual

WhartonBrooks is currently crowd-funding its latest Windows Mobile smartphone on Indiegogo. If crowdfunding isn't already a bad enough idea, a company trying to crowdfund a Windows Mobile device should be warning enough for you.
Not that anyone seems to be taking the project too seriously. With a few weeks left to run the campaign has managed to ensnare just 2% of its $1.1m target.
If you want a better indication of how few Window Mobile loyalists remain I doubt there is one. Of 3,900 Windows Phone enthusiasts Wharton Brooks was seeking for its new phone, it has managed to entice just 50.
Windows for Phones is dead, even if the corpse hasn't stopped twitching yet.